Clinical Trial Details
— Status: Not yet recruiting
Administrative data
| NCT number |
NCT05958511 |
| Other study ID # |
Thrombocytopenia |
| Secondary ID |
|
| Status |
Not yet recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
September 1, 2023 |
| Est. completion date |
December 1, 2024 |
Study information
| Verified date |
July 2023 |
| Source |
Assiut University |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
The many comorbidities in the severely ill patient also make thrombocytopenia very common (∼
40%) in intensive care unit patients. The risk of bleeding is high with severe
thrombocytopenia and is enhanced in intensive care patients with mild or moderately low
platelet counts when additional factors are present that interfere with normal hemostatic
mechanisms (eg, platelet function defects, hyperfibrinolysis, invasive procedures, or
catheters).
Description:
The many comorbidities in the severely ill patient also make thrombocytopenia very common (∼
40%) in intensive care unit patients. The risk of bleeding is high with severe
thrombocytopenia and is enhanced in intensive care patients with mild or moderately low
platelet counts when additional factors are present that interfere with normal hemostatic
mechanisms (eg, platelet function defects, hyperfibrinolysis, invasive procedures, or
catheters). Even if not associated with bleeding, low platelet counts often influence patient
management and may prompt physicians to withhold or delay necessary invasive interventions,
reduce the intensity of anticoagulation, order prophylactic platelet transfusion, or change
anticoagulants due to fear of heparin-induced thrombocytopenia.
The many comorbidities in the severely ill patient also affect platelet homeostasis, and,
consequently, thrombocytopenia is very common in critically ill patients treated in the
intensive care unit (ICU). Thrombocytopenia is usually defined as a platelet count of < 150 ×
109/L, whereas severe thrombocytopenia is considered as platelet counts < 50 × 109/L.
Thrombocytopenia has six major mechanisms, and it can be induced by hemodilution, increased
platelet consumption (both are very common in the ICU after tissue trauma, bleeding, and
disseminated intravascular coagulopathy [DIC]), increased platelet destruction (ie, immune
mechanisms), decreased platelet production, increased platelet sequestration, or by the
laboratory artefact of pseudothrombocytopenia .
